US2019241498A1PendingUtilityA1
Resveratrol esters
Est. expiryDec 24, 2035(~9.4 yrs left)· nominal 20-yr term from priority
C07C 69/40A61P 17/02C07C 67/08C07C 229/08C07C 229/36C07C 69/42
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Salts of resveratrol esters are also included.
Claims
exact text as granted — not AI-modified1 . A resveratrol ester having the following structure:
wherein R 1 , R 2 and R 3 are H or
each R 4 is independently a carbon chain of 2 to 4 carbon atoms comprising a terminal carboxylic acid moiety, a carbon chain of 1 to 5 carbon atoms comprising an amine moiety, —(CH 2 ) 3 (NH)(R 6 ), or
R 5 is a carbon chain of 3 or 4 carbon atoms having a terminal carboxylic acid moiety or a natural amino acid side chain,
R 6 is —(CO)(CH 2 ) n (CO)(OH) and where n is 1 or 2, and
at least one of R 1 , R 2 and R 3 is
and salts thereof.
2 . The resveratrol ester of claim 1 , wherein R 4 is the carbon chain of 2 to 4 carbon atoms comprising the terminal carboxylic acid moiety, and salts thereof.
3 . The resveratrol ester of claim 1 , wherein R 4 is the carbon chain of 1 to 5 carbon atoms comprising the amine moiety, and salts thereof.
4 . The resveratrol ester of claim 1 , wherein R 4 is
and R 5 is the carbon chain of 3 or 4 carbon atoms having the terminal carboxylic acid moiety, and salts thereof.
5 . The resveratrol ester of claim 2 , wherein R 4 is selected from the group consisting of —(CH 2 )(CO)(OH), —(CH 2 ) 2 (CO)(OH), and —(CH 2 ) 3 (CO)(OH).
6 . The resveratrol ester of claim 5 , wherein R 4 is —(CH 2 ) 3 (CO)(OH).
7 . The resveratrol ester of claim 2 , wherein R 1 , R 2 and R 3 are
8 . The resveratrol ester of claim 7 , wherein R 4 is selected from the group consisting of —(CH 2 )(CO)(OH), —(CH 2 ) 2 (CO)(OH), and —(CH 2 ) 3 (CO)(OH).
9 . The resveratrol ester of claim 8 , wherein R 4 is —(CH 2 ) 3 (CO)(OH).
10 . The resveratrol ester of claim 3 , wherein R 4 is selected from the group consisting of —(NH 2 )CHCH 3 , —CH(NH 2 )CH(CH 3 ) 2 , —CH(NH 2 )CH 2 CH(CH 3 ) 2 , —CH(NH 2 )CH(CH 3 )CH 2 CH 3 , —CH 2 NH 2 , —(CH 2 ) 3 (C 6 H 4 )NH 2 , —(CH 2 ) 3 NH 2 and —(CH 2 ) 5 NH 2 .
11 . The resveratrol ester of claim 10 , wherein R 4 is —CH(NH 2 )CH(CH 3 ) 2 .
12 . The resveratrol ester of claim 3 , wherein R 1 , R 2 and R 3 are
13 . The resveratrol ester of claim 12 , wherein R 4 is selected from the group consisting of —(NH 2 )CHCH 3 , —CH(NH 2 )CH(CH 3 ) 2 , —CH(NH 2 )CH 2 CH(CH 3 ) 2 , —CH(NH 2 )CH(CH 3 )CH 2 CH 3 , —CH 2 NH 2 , —(CH 2 ) 3 (C 6 H 4 )NH 2 , —(CH 2 ) 3 NH 2 and —(CH 2 ) 5 NH 2 .
14 . The resveratrol ester of claim 13 , wherein R 4 is —CH(NH 2 )CH(CH 3 ) 2 .
15 . A method of making the resveratrol ester of claim 1 , comprising:
forming the resveratrol ester from resveratrol.
16 . A composition, comprising:
the resveratrol ester of claim 2 , and a pharmaceutically acceptable carrier.
17 . (canceled)
18 . A resveratrol ester selected from the group consisting of resveratrol hemimalonate, resveratrol hemisuccinate, resveratrol hemiglutarate, resveratrol 2-aminopropanoate, resveratrol 2-amino-3-methylbutanoate, resveratrol 2-amino-4-methylpentanoate, resveratrol 2-amino-3-methylpentanoate, resveratrol aminoethanoate, resveratrol 4-(4-aminophenyl)-butyrate, resveratrol 4-amino-butyrate, and resveratrol 6-amino-hexanoate.
19 . The resveratrol ester of claim 18 , wherein the resveratrol ester is resveratrol hemiglutarate.
20 . The resveratrol ester of claim 19 , wherein the resveratrol hemiglutarate is resveratrol trihemiglutarate.
21 . (canceled)
22 . A method of reducing scar formation, comprising:
administering an effective amount of the composition of claim 16 , to a patient in need thereof.
23 . (canceled)
24 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.